F
Frank Schweizer
Researcher at University of Manitoba
Publications - 160
Citations - 6490
Frank Schweizer is an academic researcher from University of Manitoba. The author has contributed to research in topics: Efflux & Pseudomonas aeruginosa. The author has an hindex of 37, co-authored 151 publications receiving 5323 citations. Previous affiliations of Frank Schweizer include University of Lethbridge & University of Alberta.
Papers
More filters
Journal ArticleDOI
Cationic amphiphilic peptides with cancer-selective toxicity
TL;DR: The ability of CAPs to bypass established resistance mechanisms provides an attractive strategy to develop novel lead structures for cancer treatment and Peptidomimetic approaches combined with novel selective delivery devices show promise in overcoming some of these obstacles.
Journal ArticleDOI
Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination.
George G. Zhanel,George G. Zhanel,Christopher D. Lawson,Heather J. Adam,Heather J. Adam,Frank Schweizer,Sheryl A. Zelenitsky,Philippe Lagacé-Wiens,Andrew J Denisuik,Ethan Rubinstein,Ethan Rubinstein,Alfred S. Gin,Alfred S. Gin,Daryl J. Hoban,Daryl J. Hoban,Joseph P. Lynch,James A. Karlowsky,James A. Karlowsky +17 more
TL;DR: Pharmacodynamic data suggest that ceftazidime-avibactam is rapidly bactericidal versus β-lactamase-producing Gram-negative bacilli that are not inhibited by ceftAZidime alone.
Journal ArticleDOI
Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli
George G. Zhanel,George G. Zhanel,Phillip Chung,Heather J. Adam,Heather J. Adam,Sheryl A. Zelenitsky,Andrew J Denisuik,Frank Schweizer,Philippe Lagacé-Wiens,Ethan Rubinstein,Ethan Rubinstein,Alfred S. Gin,Alfred S. Gin,Andrew Walkty,Andrew Walkty,Daryl J. Hoban,Daryl J. Hoban,Joseph P. Lynch,James A. Karlowsky +18 more
TL;DR: Time-kill experiments and animal infection models have demonstrated that the pharmacokinetic–pharmacodynamic index that is best correlated with ceftolozane’s in vivo efficacy is the percentage of time in which free plasma drug concentrations exceed the minimum inhibitory concentration of a given pathogen, as expected of β-lactams.
Journal ArticleDOI
New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.
George G. Zhanel,Divna Calic,Frank Schweizer,Sheryl A. Zelenitsky,Heather J. Adam,Philippe Lagacé-Wiens,Ethan Rubinstein,Alfred S. Gin,Daryl J. Hoban,James A. Karlowsky +9 more
TL;DR: Clinical trials involving patients with complicated skin and skin structure infections (cSSSIs) have demonstrated that all three agents are as efficacious as comparators, and the most common adverse effects reported with dalbavancin use included nausea, diarrhoea and constipation.
Journal ArticleDOI
Cationic Amphiphiles, a New Generation of Antimicrobials Inspired by the Natural Antimicrobial Peptide Scaffold
TL;DR: Cationic amphiphiles promise to provide a new and rich source of diverse antibacterial lead structures in the years to come.